NeuPath Health Inc. Unveils Q1 2025 Financials Amid Market Volatility and Growth Challenges
NeuPath Health Inc. has reported its Q1 2025 financial results, showing a stock price of 0.23 CAD and a negative price-to-earnings ratio, but remains committed to its mission of providing chronic pain management services.
2 minutes to read